What is Medtronic plc's P/E and P/B ratio?

Medtronic plc has a P/E ratio of 23.7 and a P/B ratio of 2.46.

What is Medtronic plc's debt-to-equity ratio?

Medtronic plc has a debt-to-equity ratio of 0.55.

How much does Medtronic plc owe compared with what it owns?

Medtronic plc owes $0.46 for every $1 it owns (balance sheet Jul 2026), which is low.

Does Medtronic plc have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Medtronic plc.

Where can I read the latest news about Medtronic plc?

Recent headlines about Medtronic plc from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Medtronic plc have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Medtronic plc's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Medtronic plc (MDT) Stock Price Analysis

Q: What is Medtronic plc's Positivity rank?

Medtronic plc is ranked #4,284 of 6,767 companies globally and #6 of 17 in Ireland on PositoAI, with a Positivity Score of 19,665.

Medtronic plc — Overview & Financial Snapshot

Medtronic plc (NYSE: MDT) is a Healthcare company, ranked #4,284 of 6,767 companies globally and #6 of 17 in Ireland on PositoAI, with a Positivity Score of 19,665. Its market capitalisation is ₹11.66 lakh Cr ($123.55B), P/E ratio is 23.7 and P/B ratio is 2.46. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Powered by OpenAI

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Medtronic plc